Anti-obesity and Gut Microbiota Modulation Effect of Astragalus Polysaccharides Combined with Berberine on High-Fat Diet-Fed Obese Mice.
10.1007/s11655-021-3303-z
- Author:
Shi-Jun YUE
1
;
Wen-Xiao WANG
2
;
Lei ZHANG
1
;
Juan LIU
1
;
Wu-Wen FENG
1
;
Huan GAO
2
;
Yu-Ping TANG
2
;
Dan YAN
3
Author Information
1. Beijing Key Laboratory of Bio-characteristic Profiling for Evaluation of Rational Drug Use, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
2. Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi University of Chinese Medicine, Xi'an, 712046, China.
3. Beijing Key Laboratory of Bio-characteristic Profiling for Evaluation of Rational Drug Use, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China. yd277@126.com.
- Publication Type:Journal Article
- Keywords:
Astragalus polysaccharides;
Bacteroides;
berberine;
gut microbiota;
obesity
- MeSH:
Mice;
Animals;
Diet, High-Fat;
Berberine/therapeutic use*;
Mice, Obese;
RNA, Ribosomal, 16S/genetics*;
Gastrointestinal Microbiome;
Obesity/drug therapy*;
Insulin Resistance;
Mice, Inbred C57BL
- From:
Chinese journal of integrative medicine
2023;29(7):617-625
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate whether astragalus polysaccharides (APS) combined with berberine (BBR) can reduce high-fat diet (HFD)-induced obesity in mice.
METHODS:Except for normal mice, 32 HFD-induced obese mice were randomized into HFD, APS (1,000 mg/kg APS), BBR (200 mg/kg BBR), and APS plus BBR (1,000 mg/kg APS plus 200 mg/kg BBR) groups, respectively. After 6-week treatment (once daily by gavage), the obesity phenotype and pharmacodynamic effects were evaluated by histopathological examination of epididymal fat, liver, and colon using hematoxylin-eosin staining and serum biochemical analyses by an automated chemistry analyzer. The feces were collected at the 12 th week, and taxonomic and functional profiles of gut microbiota were analyzed by 16S ribosomal ribonucleic acid (16S rRNA) sequencing.
RESULTS:Compared with HFD group, the average body weight of APS plus BBR group was decreased (P<0.01), accompanied with the reduced fat accumulation, enhanced colonic integrity, insulin sensitivity and glucose homeostasis (P<0.05 or P<0.01). Importantly, APS combined with BBR treatment was more effective than APS or BBR alone in improving HFD-induced insulin resistance (P<0.05 or P<0.01). 16S rRNA sequence-based analysis of fecal samples demonstrated that APS combined with BBR treatment exhibited a better impact on HFD-induced gut microbiota dysbiosis, exclusively via the enriched abundances of Bacteroides, which corresponded to the large increase of predicted bacterial genes involved in carbohydrate metabolism.
CONCLUSION:APS combined with BBR may synergistically reduce obesity and modulate the gut microbiota in HFD-fed mice.
